Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 2/2020

12.12.2019 | Review Article

Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris

verfasst von: Dustin H. Marks, Sonya Prasad, Brianna De Souza, Laura J. Burns, Maryanne M. Senna

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Androgenetic alopecia (AGA) and acne vulgaris are two conditions commonly seen by dermatologists. Androgens and the androgen receptors play an essential role in the manifestation of both conditions, and some systemic therapies function by interfering in this pathway. The use of topical antiandrogen therapies has gained traction in recent years due to their potential efficacy in treating AGA and acne vulgaris, as well as their reduced adverse effects compared with systemic drugs. This review discusses the role of androgens in skin physiology and pathology and assesses the potential efficacy and safety of three topical antiandrogen therapies in the treatment of AGA and acne vulgaris. A literature review utilizing the PubMed, US Clinical Trials, and SCOPUS databases was conducted to search for randomized clinical trials, systematic reviews, cohort studies, case reports, and other relevant published studies on the pathogenesis and treatment of each condition with topical finasteride, ketoconazole shampoo, and cortexolone 17α-propionate (C17P). The results demonstrated that topical formulations of finasteride, ketoconazole, and C17P are promising treatments for male pattern hair loss, especially topical finasteride in combination with topical minoxidil. Limited studies have shown C17P to have potential in treating acne vulgaris in both males and females. Minimal adverse effects have been reported in clinical trials for all topical therapies, although topical finasteride is still contraindicated in pregnancy. Recognizing the preliminary evidence, more peer-reviewed studies on topical antiandrogen treatments for AGA and acne vulgaris are necessary before definitive recommendations can be made regarding efficacy and safety. There is also a critical need to include more women in study populations for these treatments.
Literatur
1.
Randall VA. Androgens and human hair growth. Clin Endocrinol (Oxf). 1994;40(4):439–57.PubMed
2.
Zouboulis CC, Degitz K. Androgen action on human skin: from basic research to clinical significance. Exp Dermatol. 2004;13(Suppl 4):5–10.PubMed
3.
Lai J-J, Chang P, Lai K-P, Chen L, Chang C. The role of androgen and androgen receptor in the skin-related disorders. Arch Dermatol Res. 2012;304(7):499–510.PubMedPubMedCentral
4.
Zouboulis CC. Human skin: an independent peripheral endocrine organ. Horm Res. 2000;54(5–6):230–42.PubMed
5.
Zouboulis CC, Chen W-C, Thornton MJ, Qin K, Rosenfield R. Sexual hormones in human skin. Horm Metab Res. 2007;39(2):85–95.PubMed
6.
Liang T, Hoyer S, Yu R, et al. Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor. J Invest Dermatol. 1993;100(5):663–6.PubMed
7.
Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007;28(7):778–808.PubMed
8.
Choudhry R, Hodgins MB, Van der Kwast TH, Brinkmann AO, Boersma WJ. Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol. 1992;133(3):467–75.PubMed
9.
Chen W, Zouboulis CC, Orfanos CE. The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Dermatol Basel Switz. 1996;193(3):177–84.
10.
Picardo M, Ottaviani M, Camera E, Mastrofrancesco A. Sebaceous gland lipids. Dermatoendocrinol. 2009;1(2):68–71.PubMedPubMedCentral
11.
Zouboulis CC, Baron JM, Böhm M, et al. Frontiers in sebaceous gland biology and pathology. Exp Dermatol. 2008;17(6):542–51.PubMed
12.
Makrantonaki E, Ganceviciene R, Zouboulis C. An update on the role of the sebaceous gland in the pathogenesis of acne. Dermatoendocrinol. 2011;3(1):41–9.PubMedPubMedCentral
13.
Knor T. The pathogenesis of acne. Acta Dermatovenerol Croat. 2005;13(1):44–9.PubMed
14.
Dréno B, Pécastaings S, Corvec S, Veraldi S, Khammari A, Roques C. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: a brief look at the latest updates. J Eur Acad Dermatol Venereol. 2018;32(S2):5–14.PubMed
15.
Stewart ME. Sebaceous gland lipids. Semin Dermatol. 1992;11(2):100–5.PubMed
16.
Downing DT, Stewart ME, Wertz PW, Strauss JS. Essential fatty acids and acne. J Am Acad Dermatol. 1986;14(2 Pt 1):221–5.PubMed
17.
Sansone G, Reisner RM. Differential rates of conversion of testosterone to dihydrotestosterone in acne and in normal human skin: a possible pathogenic factor in acne. J Invest Dermatol. 1971;56(5):366–72.PubMed
18.
Lookingbill DP, Horton R, Demers LM, Egan N, Marks JG, Santen RJ. Tissue production of androgens in women with acne. J Am Acad Dermatol. 1985;12(3):481–7.PubMed
19.
Randall VA. Androgens and hair growth. Dermatol Ther. 2008;21(5):314–28.PubMed
20.
Sawers RA, Randall VA, Iqbal MJ. Studies on the clinical and endocrine aspects of antiandrogens. In: Jeffcoate SL, editor. Androgens and antiandrogen therapy. Current topics in endocrinology, vol. 1. Chichester: John Wiley; 1982. p. 145–68.
21.
Reynolds EL. The appearance of adult patterns of body hair in man. Ann N Y Acad Sci. 1951;53(3):576–84.PubMed
22.
Hamilton JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci. 1951;53(3):708–28.PubMed
23.
Orentreich N, Durr NP. Biology of scalp hair growth. Clin Plast Surg. 1982;9(2):197–205.PubMed
24.
Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44(235):291–303.PubMedPubMedCentral
25.
Ellis JA, Stebbing M, Harrap SB. Genetic analysis of male pattern baldness and the 5alpha-reductase genes. J Invest Dermatol. 1998;110(6):849–53.PubMed
26.
27.
Olsen EA. Disorders of hair growth: diagnosis and treatment. 2nd ed. New York: McGraw-Hill, Medical Publishing Division; 2003.
28.
Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest. 1993;92(2):903–10.PubMedPubMedCentral
29.
Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997;109(3):296–300.PubMed
30.
Yip L, Rufaut N, Sinclair R. Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know: Update on androgenetic alopecia. Australas J Dermatol. 2011;52(2):81–8.PubMed
31.
Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005;52(2):301–11.PubMed
32.
Fabbrocini G, Cantelli M, Masarà A, Annunziata MC, Marasca C, Cacciapuoti S. Female pattern hair loss: a clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol. 2018;4(4):203–11.PubMedPubMedCentral
33.
Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136–141.e5.PubMed
34.
Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000;43(5 Pt 1):768–76.PubMed
35.
Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril. 2003;79(1):91–5.PubMed
36.
Hu AC, Chapman LW, Mesinkovska NA. The efficacy and use of finasteride in women: a systematic review. Int J Dermatol. 2019;58(7):759–76.PubMed
37.
Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. J Drugs Dermatol. 2018;17(4):457–63.PubMedPubMedCentral
38.
Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther. 2016;54(1):19–27.PubMed
39.
40.
Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014;52(10):842–9.PubMed
41.
Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018;32(12):2257–63.PubMed
42.
Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. Am J Clin Dermatol. 2019;20(1):147–53.PubMed
43.
Mazzarella GF, Loconsole GF, Cammisa GA, Mastrolonardo GM, Vena G. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. J Dermatol Treat. 1997;8(3):189–92.
44.
Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2009;75(1):47–51.PubMed
45.
Chandrashekar BS, Nandhini T, Vasanth V, Sriram R, Navale S. Topical minoxidil fortified with finasteride: an account of maintenance of hair density after replacing oral finasteride. Indian Dermatol Online J. 2015;6(1):17–20.PubMedPubMedCentral
46.
Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil/0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. J Med Assoc Thai. 2012;95(10):1312–6.PubMed
47.
48.
Piérard-Franchimont C, De Doncker P, Cauwenbergh G, Piérard GE. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 1998;196(4):474–7.PubMed
49.
Debruyne FM, Witjes FA. Ketoconazole high dose (H.D.) in the management of hormonally pretreated patients with progressive metastatic prostate cancer. Prog Clin Biol Res. 1987;243A:301–13.PubMed
50.
Hugo Perez BS. Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. Med Hypotheses. 2004;62(1):112–5.PubMed
51.
Ayub M, Levell MJ. The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins. J Steroid Biochem. 1989;33(2):251–5.PubMed
52.
Eil C. Ketoconazole binds to the human androgen receptor. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 1992;24(8):367–70.
53.
54.
Ghetti P, Patrone P, Tosti A. Ketoconazole in the Treatment of Acne in Women. Arch Dermatol. 1986;122(6):629–629.PubMed
55.
Vidal-Puig AJ, Muñoz-Torres M, Jódar-Gimeno E, et al. Ketoconazole therapy: hormonal and clinical effects in non-tumoral hyperandrogenism. Eur J Endocrinol. 1994;130(4):333–8.PubMed
56.
Venturoli S, Fabbri R, Dal Prato L, et al. Ketoconazole therapy for women with acne and/or hirsutism. J Clin Endocrinol Metab. 1990;71(2):335–9.PubMed
57.
Unno M, Cho O, Sugita T. Inhibition of Propionibacterium acnes lipase activity by the antifungal agent ketoconazole. Microbiol Immunol. 2017;61(1):42–4.PubMed
58.
Akaza N, Akamatsu H, Numata S, et al. Microorganisms inhabiting follicular contents of facial acne are not only Propionibacterium but also Malassezia spp. J Dermatol. 2016;43(8):906–11.PubMed
59.
60.
61.
Rosette C, Agan FJ, Mazzetti A, Moro L, Gerloni M. Cortexolone 17α-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs Dermatol. 2019;18(5):412–8.PubMed
62.
Rosette C, Rosette N, Mazzetti A, Moro L, Gerloni M. Cortexolone 17α-propionate (clascoterone) is an androgen receptor antagonist in dermal papilla cells in vitro. J Drugs Dermatol. 2019;18(2):197–201.PubMed
63.
Mazzetti A, Moro L, Gerloni M, Cartwright M. A phase 2b, randomized, double-blind vehicle controlled, dose escalation study evaluating clascoterone 0.1%, 0.5%, and 1% topical cream in subjects With facial acne. J Drugs Dermatol. 2019;18(6):570.PubMed
64.
65.
Mazzetti A, Moro L, Gerloni M, Cartwright M. Pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17-alpha propionate, CB-03-01) topical cream, 1% in subjects with acne vulgaris: an open-label phase 2a study. J Drugs Dermatol. 2019;18(6):563.PubMed
66.
Metadaten
Titel
Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris
verfasst von
Dustin H. Marks
Sonya Prasad
Brianna De Souza
Laura J. Burns
Maryanne M. Senna
Publikationsdatum
12.12.2019
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 2/2020
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-019-00493-z

Weitere Artikel der Ausgabe 2/2020

American Journal of Clinical Dermatology 2/2020 Zur Ausgabe

Leading Article

Updates on Botulinum Neurotoxins in Dermatology

Short Communication

Retrospective Case Series on Risk Factors, Diagnosis and Treatment of Pseudomonas aeruginosa Nail Infections

Review Article

Generalized Pustular Psoriasis: Clinical Management and Update on Autoinflammatory Aspects

Original Research Article

Malignant Melanoma of the Vulva and Vagina: A US Population-Based Study of 1863 Patients

Systematic Review

Drug-Induced Intracranial Hypertension: A Systematic Review and Critical Assessment of Drug-Induced Causes

Review Article

Laser and Light-Based Treatment Modalities for the Management of Hidradenitis Suppurativa

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise